NEW YORK (GenomeWeb) – Lucence Diagnostics said today that it has entered a partnership with genetic testing lab Bangkok Molecular Genetics to make its blood-based cancer diagnosis and screening tests available to patients in Thailand.
Under the terms of the agreement, BMG will distribute Lucence's blood tests, which involve the detection of DNA fragments shed by a tumor into the blood and target the most common cancers in Asia, such as breast, colon, lung, and nasopharyngeal cancer.
Financial and other terms of the agreement were not disclosed.
The distribution deal in Thailand comes after a similar announcement by Lucence that Singapore's Quest Laboratories would offer its tests to customers in that region.